$266 Million is the total value of DAFNA Capital Management LLC's 87 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| STXS | STEREOTAXIS INC | $39,673,000 | +48.7% | 13,680,554 | 0.0% | 14.91% | +29.6% | |
| SAGE | SAGE THERAPEUTICS INC | $22,668,000 | +15.1% | 123,806 | 0.0% | 8.52% | +0.3% | |
| ATRC | ATRICURE INC | $9,511,000 | +11.4% | 318,729 | 0.0% | 3.58% | -3.0% | |
| IBB | ISHARES TR NASDAQ BIOTECHetf | $6,699,000 | -2.4% | 61,400 | 0.0% | 2.52% | -15.0% | |
| ARNA | ARENA PHARMACEUTICALS INC | $5,508,000 | +30.8% | 93,942 | 0.0% | 2.07% | +13.9% | |
| RADIUS HEALTH INCnote 3.000% 9/0 | $3,624,000 | +8.6% | 4,000,000 | 0.0% | 1.36% | -5.4% | ||
| MNLO | MENLO THERAPEUTICS INC | $3,594,000 | -23.7% | 600,030 | 0.0% | 1.35% | -33.5% | |
| XENE | XENON PHARMACEUTICALS INC | $3,260,000 | -3.0% | 330,667 | 0.0% | 1.22% | -15.5% | |
| PRQR | PROQR THERAPEUTICS N V | $2,380,000 | -34.4% | 261,521 | 0.0% | 0.90% | -42.8% | |
| FOMX | FOAMIX PHARMACEUTICALS LTD | $1,923,000 | -36.5% | 808,000 | 0.0% | 0.72% | -44.7% | |
| SCYX | SCYNEXIS INC | $1,668,000 | -13.2% | 1,272,927 | 0.0% | 0.63% | -24.4% | |
| AGTC | APPLIED GENETIC TECHNOL CORP | $1,361,000 | -9.6% | 359,190 | 0.0% | 0.51% | -21.1% | |
| JNJ | JOHNSON AND JOHNSON | $1,309,000 | -0.4% | 9,400 | 0.0% | 0.49% | -13.2% | |
| NTUS | NATUS MEDICAL INC | $1,102,000 | +1.2% | 42,900 | 0.0% | 0.41% | -11.9% | |
| MGNX | MACROGENICS INC | $849,000 | -5.6% | 50,000 | 0.0% | 0.32% | -17.8% | |
| SPRO | SPERO THERAPEUTICS INC | $806,000 | -10.1% | 70,000 | 0.0% | 0.30% | -21.7% | |
| MDGL | MADRIGAL PHARMACEUTICALS INC | $692,000 | -16.3% | 6,600 | 0.0% | 0.26% | -27.2% | |
| ASMB | ASSEMBLY BIOSCIENCES INC | $682,000 | -31.5% | 50,573 | 0.0% | 0.26% | -40.5% | |
| URGN | UROGEN PHARMA LTD | $539,000 | -2.7% | 15,000 | 0.0% | 0.20% | -15.1% | |
| MASI | MASIMO CORPORATION | $446,000 | +7.5% | 3,000 | 0.0% | 0.17% | -6.1% | |
| DEXCOM INCnote 0.750% 5/1 | $399,000 | +18.8% | 250,000 | 0.0% | 0.15% | +3.4% | ||
| STRO | SUTRO BIOPHARMA INC | $358,000 | -0.3% | 31,494 | 0.0% | 0.14% | -12.9% | |
| RIGL | RIGEL PHARMACEUTICALS INC | $359,000 | +1.4% | 137,600 | 0.0% | 0.14% | -11.8% | |
| CDTX | CIDARA THERAPEUTICS INC | $357,000 | -36.7% | 212,766 | 0.0% | 0.13% | -44.9% | |
| SLGL | SOL GEL TECHNOLOGIES LTD | $319,000 | +34.6% | 35,000 | 0.0% | 0.12% | +17.6% | |
| ALDX | ALDEYRA THERAPEUTICS INC | $300,000 | -33.6% | 50,000 | 0.0% | 0.11% | -42.1% | |
| ALDER BIOPHARMACEUTICALS INCnote 2.500% 2/0 | $232,000 | -3.3% | 250,000 | 0.0% | 0.09% | -16.3% | ||
| BTX | BIOTIME INC | $105,000 | -15.3% | 95,000 | 0.0% | 0.04% | -26.4% | |
| ALRN | AILERON THERAPEUTICS INC | $72,000 | -62.9% | 99,502 | 0.0% | 0.03% | -67.9% | |
| BLCM | BELLICUM PHARMACEUTICALS INC | $51,000 | -49.5% | 30,000 | 0.0% | 0.02% | -56.8% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.